Earnings Summary

Inovio Pharmaceuticals, Inc.’s revenue fell -17.66% since last year same period to $0.1Mn in the Q4 2023. On a quarterly growth basis, Inovio Pharmaceuticals, Inc. has generated -73.57% fall in its revenue since last 3-months.

Inovio Pharmaceuticals, Inc.’s net profit jumped 51.61% since last year same period to $-25Mn in the Q4 2023. On a quarterly growth basis, Inovio Pharmaceuticals, Inc. has generated 26.31% jump in its net profits since last 3-months.

Inovio Pharmaceuticals, Inc.’s net profit margin jumped 41.23% since last year same period to -24357.91% in the Q4 2023. On a quarterly growth basis, Inovio Pharmaceuticals, Inc. has generated -178.86% fall in its net profit margins since last 3-months.

Inovio Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.99 - a 22.05% jump from last quarter’s estimates.

Inovio Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.99.

Inovio Pharmaceuticals, Inc.’s earning per share (EPS) fell -433.33% since last year same period to -1.12 in the Q4 2023. This indicates that the Inovio Pharmaceuticals, Inc. has generated -433.33% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Inovio Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.32.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Inovio Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.8.